Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer
Is a
Allocation Type
NA
0
Health Conditions in Trial
Intervention Model
Single Group Assignment
0
Interventional Trial Phase
Phase 2
0
Interventional Trial Purpose
Prevention
0
Intervention Treatment
Vytorin
0
Intervention Type
Drug
0
Last Updated
May 31, 2024
0
Masking Type
None (Open Label)
0
Primary Completion Date
February 29, 2028
0
Trial Recruitment Size
140
0
Trial Sponsor
Clinical Trial Start Date
July 1, 2024
0
Study Completion Date
May 31, 2028
0
Clinical Trial Study Type
Interventional
0
NCT Number
Official Name
Lowering Cholesterol in Prostate Cancer to Target Rapamycin-Insensitive Companion Of MTOR (TORC2) in T-Cell Surface Glycoprotein CD8 Alpha Chain (CD8+) Lymphocytes
0
Official Website
Find more entities like Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.